IPATASERTIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H32ClN5O2
Molecular Weight	457.996
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NC[C@@H](C(=O)N1CCN(CC1)C2=NC=NC3=C2[C@H](C)C[C@H]3O)C4=CC=C(Cl)C=C4

InChI

InChIKey=GRZXWCHAXNAUHY-NSISKUIASA-N

InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.arraybiopharma.com/product-pipeline/other-compounds/ipatasertib-gdc-0068/
Curator's Comment: description was created based on several sources, including: https://www.biooncology.com/pipeline-molecules/ipatasertib.html | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=669600 | http://meetinglibrary.asco.org/content/152669-156

Ipatasertib, an investigational Akt inhibitor, is currently in clinical development based on its potential to specifically target Akt in tumors with activated Akt signaling. Preclinical data have shown that ipatasertib selectively decreased cell viability and increased apoptosis in tumor cell lines characterized by activated Akt. Ipatasertib is advancing in clinical development including three Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer. The most commonly reported adverse events associated with Ipatasertib were Grade 1-2 diarrhea, nausea, fatigue, vomiting, decreased appetite and rash.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serine/threonine-protein kinase AKT 31 Target ID: CHEMBL4282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22934575 \| DOI: 10.1158/1538-7445.AM2011-DDT02-01	Inhibitor 8504	5.0 nM [IC50]
Serine/threonine-protein kinase AKT2 17 Target ID: CHEMBL2431 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22934575 \| DOI: 10.1158/1538-7445.AM2011-DDT02-01	Inhibitor 8504	18.0 nM [IC50]
Serine/threonine-protein kinase AKT3 17 Target ID: CHEMBL4816 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22934575 \| DOI: 10.1158/1538-7445.AM2011-DDT02-01	Inhibitor 8504	8.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 432 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02162719 http://adisinsight.springer.com/drugs/800031868 http://www.arraybiopharma.com/product-pipeline/other-compounds/ipatasertib-gdc-0068/	Primary	Phase II 1147	Unknown Approved Use Unknown
Prostate cancer 186 Sources: http://adisinsight.springer.com/drugs/800031868 http://www.arraybiopharma.com/product-pipeline/other-compounds/ipatasertib-gdc-0068/	Primary	Phase II 1147	Unknown Approved Use Unknown
Gastric cancer 53 Sources: http://adisinsight.springer.com/drugs/800031868 http://www.arraybiopharma.com/product-pipeline/other-compounds/ipatasertib-gdc-0068/	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
953 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31227862	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		IPATASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
973 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31227862	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		IPATASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
5930 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31227862	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		IPATASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6510 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31227862	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		IPATASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
21.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31227862	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		IPATASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.06 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31227862	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		IPATASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY116329	https://www.001chemical.com/chem/search?q=DY116329
1PlusChem LLC	1P0001H0	https://www.1pchem.com/search?query=1P0001H0
AChemBlock	10323	http://www.achemblock.com/catalogsearch/result/?q=10323
AChemBlock	O32846	http://www.achemblock.com/catalogsearch/result/?q=O32846
AK Scientific	SYN5726	https://aksci.com/item_detail.php?cat=SYN5726
AK Scientific	X6541	https://aksci.com/item_detail.php?cat=X6541
Ambeed	A115731	http://www.ambeed.com/search/Search.html?keyword=A115731
Angene	AGN-PC-0WADDY	http://www.angenechemical.com/productshow/AGN-PC-0WADDY.html
AOBIOUS INC	AOB87386	http://aobious.com/aobious/search?search_query=AOB87386
AstaTech	43294	http://astatechinc.com/CPSResult.php?CRNO=43294
BLD Pharm	BD304089	http://www.bldpharm.com/search/Search.html?keyword=BD304089
BLD Pharm	BD630219	http://www.bldpharm.com/search/Search.html?keyword=BD630219
BOC Sciences	1001264-89-6	http://www.bocsci.com/description.asp?cas=1001264-89-6
Cayman Chemical	18412	http://www.caymanchem.com/app/template/Product.vm/catalog/18412
Chem Scene	CS-0975	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0975
Chem Scene	CS-4037	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-4037
ChemShuttle	104905	https://www.chemshuttle.com/catalogsearch/result/?q=104905
eMolecules	233175521	https://orderbb.emolecules.com/search/#?query=233175521
eMolecules	44786321	https://orderbb.emolecules.com/search/#?query=44786321
eMolecules	53744910	https://orderbb.emolecules.com/search/#?query=53744910
eNovation Chemicals	D296900	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D296900&searchbtn.x=0&searchbtn.y=0
KeyOrganics	AS-17027	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-17027
Matrix Scientific	145252	http://www.matrixscientific.com/145252.html
mcule	MCULE-2336609784	https://mcule.com/MCULE-2336609784/
mcule	MCULE-7295297337	https://mcule.com/MCULE-7295297337/
mcule	MCULE-8925317592	https://mcule.com/MCULE-8925317592/
mcule	MCULE-9451391100	https://mcule.com/MCULE-9451391100/
MedChem Express	HY-15186	https://www.medchemexpress.com/search.html?q=HY-15186A&ft=&fa=&fp=
MedChem Express	HY-15186A	https://www.medchemexpress.com/search.html?q=HY-15186A&ft=&fa=&fp=
Molcore	MC116329	http://www.molcore.com/CatMC116329.html
Molnova	M10012	https://www.molnova.com/en/serch-list.html?keywords=M10012
MolPort	MolPort-023-219-187	https://www.molport.com/shop/molecule-link/MolPort-023-219-187
MolPort	MolPort-046-417-033	https://www.molport.com/shop/molecule-link/MolPort-046-417-033
MuseChem	I007347	https://www.musechem.com/product/I007347.html
TargetMol	T6252	https://www.targetmol.com/search?keyword=T6252
Toronto Research Chemicals	C377870	https://www.trc-canada.com/product-detail/?CatNum=C377870
Toronto Research Chemicals	D289422	https://www.trc-canada.com/product-detail/?CatNum=D289422
Wonderchem	WC-009UL0	http://www.wonder-chem.com/search.html?text=WC-009UL0

PubMed

Title	Date	PubMed
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.	2012-09-27	22934575

Patents

Sample Use Guides

In Vivo Use Guide

600 mg once daily on days 1 to 7 of each 14-day cycle

Route of Administration: Oral

In Vitro Use Guide

Ipatasertib has a potent antiproliferative effect on LNCaP cells with an IC50 of 95 ± 16 nM. In PC3, MCF7-neo/HER2, and BT474M1 cell lines, Ipatasertib was able to inhibit overall viability with IC50 values in the range of 1−4 uM.

Name

Type

Language

RG-7440

Preferred Name

English

IPATASERTIB

Official Name

English

(2S)-2-(4-CHLOROPHENYL)-1-(4-((5R,7R)-7-HYDROXY-5-METHYL-6,7-DIHYDRO-5H-CYCLOPENTA(D)PYRIMIDIN-4-YL)PIPERAZIN-1-YL(-3-((PROPAN-2-YL)AMINO)PROPAN-1-ONE

Common Name

English

Ipatasertib [WHO-DD]

Common Name

English

1-PROPANONE, 2-(4-CHLOROPHENYL)-1-(4-((5R,7R)-6,7-DIHYDRO-7-HYDROXY-5-METHYL-5H-CYCLOPENTAPYRIMIDIN-4-YL)-1-PIPERAZINYL)-3-((1-METHYLETHYL)AMINO)-, (2S)-

Systematic Name

English

ipatasertib [INN]

Common Name

English

GDC-0068

Code

English

RG7440

Code

English

IPATASERTIB [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C155764